evo真人视讯

Professor Shi Yuanyuan of Shenzhen Cell Valley Group Invited to Attend Cornell-China Forum to Discuss Biomedical Innovation Translation

Date:11-16  Hits:  Belong to:News

图片.png

Recently, the Cornell-China Forum was successfully held. At the forum, Kavita Bala, Provost of Cornell University; Wang Zhizhen and Shi Songhai, Academicians of the Chinese Academy of Sciences; Andrew Karolyi, Dean of the Johnson Graduate School of Management; and other Chinese and international guests attended and delivered speeches. The topics covered global emerging markets, business and cultural tourism, and platforms and organizations in the digital economy. Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley Group, was invited to attend as a roundtable speaker, engaging in in-depth dialogue with scholars from domestic and overseas universities, industry leaders, and industry experts, and sharing industrial practice insights on topics including frontier technologies in cell and gene therapy, industry-academia-research collaboration in biomedicine, and international innovation cooperation.

The Cornell-China Forum is a signature international exchange platform of the Cornell University China Center. It has long brought together elites from academia and industry at home and abroad, focusing on topics including frontier technological innovation, interdisciplinary collaboration, and industrial implementation, building a bridge for two-way China-international exchange and intellectual collision, and promoting the efficient linkage of research achievements, talent resources, and industrial capital.

During the roundtable exchange, Professor Shi Yuanyuan, drawing on Shenzhen Cell Valley Group's full-chain layout in the CGT field, shared insights on core topics including industrial-scale production of cell therapy, clinical translation pathways for pipelines such as NK/CAR-NK and exosomes, the implementation of domestic policies on emerging biomedical technologies, and the standardized development of the cell industry. He noted that cell and gene therapy has entered a stage of accelerated industrialization, where technological innovation, quality systems, compliance capabilities, and clinical resources are the core foundations for industrial implementation. At the same time, international academic exchange and cross-sector industry-academia-research collaboration can better help frontier technologies overcome bottlenecks, driving innovative therapies from the laboratory to the clinic and benefiting more patients.

During the exchange, Professor Shi Yuanyuan also introduced Shenzhen Cell Valley Group's core platform capabilities: leveraging proprietary viral vector technology, GMP cell preparation platforms, and extensive clinical research service experience, the company continuously provides integrated translation services—including CMC development, process translation, co-development of in-hospital cell platforms, and project applications—to medical institutions and research teams, consistently closing the loop of "basic research—clinical research—industrial implementation."

图片.png

This participation marks an important step for the Cell Valley Group in continuously deepening international academic exchange and connecting global innovation resources. Going forward, the Cell Valley Group will continue to uphold an open and collaborative philosophy, continuously strengthen linkages with top universities, research institutions, and clinical experts at home and abroad, deepen the translation of cell and gene therapy technologies, and empower the high-quality development of the domestic biopharmaceutical industry through technological innovation.

图片.png图片.png


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software